Skip to main content

Charles River Laboratories statistics

  • CRL · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$337.97−0.83%Close 13 Nov 2026 · Market value $16.06B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Charles River Laboratories is valued at $16.06B on its latest close. Its price is 399.6 times its earnings.

Market value$16.06B
Enterprise value$18.88B
Price / earnings399.57
Price / sales4.04
Price / book4.98
EV / EBITDA42.52
EV / sales4.75
Price / free cash flow40.18
Price / free cash flow, own 5-year average27.34
EV / EBIT117.67
EV / free cash flow46.81
Free cash flow yield2.5%

Share price

Latest close$337.97
Day's change−0.8%
52-week high$379.63
52-week low$146.20
From 52-week high−11.0%
Return · 1 month+12.6%
Return · 3 months+16.0%
Return · year to date+69.4%
Return · 1 year+97.1%
Beta · 1 year against the S&P 5001.27
50-day average$311.06
200-day average$227.71
RSI 1452.5
Average volume · 20 sessions1.3M

Margins and returns

For fiscal 2025, as filed.

Gross margin33.0%
Operating margin0.6%
Net margin−3.6%
Free cash flow margin12.9%
Return on equity−4.4%
Return on assets0.3%
Return on invested capital0.3%
Return on invested capital, 5-year average5.5%
Return on capital employed0.4%
Stock-based compensation / revenue1.8%

Financial position

At the end of fiscal 2025.

Cash and equivalents$213.8M
Total debt$2.63B
Net debt$2.41B
Current ratio1.29
Quick ratio0.86
Debt / equity0.83
Net debt / EBITDA5.64
Interest coverage0.24

Growth

Revenue, latest quarter on a year−2.2%
Revenue, twelve months on a year−1.2%
EPS, latest quarter on a year+524%
Revenue, 5-year compound+6.5%
Revenue, 10-year compound+11.4%
Free cash flow, 5-year compound+6.4%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares49.6M
Shares outstanding, 5-year compound−0.4%
Net share repurchases$360.0M

Taxes

For fiscal 2025, as filed.

Income tax expense$42.66M
Effective tax rate−42.9%

CRL in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.